<DOC>
	<DOCNO>NCT00365612</DOCNO>
	<brief_summary>To compare effectiveness ( efficacy , safety &amp; tolerability ) Single Tablet Regimen efavirenz/emtricitabine/tenofovir DF subject continue unmodified HAART measure proportion patient maintain viral load ( HIV-1 RNA ) &lt; 200 copies/mL Week 48 .</brief_summary>
	<brief_title>Single Tablet Regimen ( STR ) Simplification Study HIV-1 Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Efavirenz , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>HIV1 positive patient maintain HIV1 viral load &lt; 200 copies/mL , least 3 month . Patients must first HAART documented viral suppression PIbased regimen time prior change therapy . HAART must consist either : 1 . A PI ( without ritonavir ) + least 2 NRTIs 2 . An NNRTI + least 2 NRTIs . Negative serum pregnancy test . Patients take NNRTI prior current therapy . Patients take NRTIonly therapy great 7 day prior current therapy . Patients currently take EFV+FTC+TDF . Patients creatinine clearance &lt; 60 mL/min CockcroftGault estimation . Patients experience virologic failure previous ARV therapy . Patients document resistance study agent time past .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>HIV</keyword>
	<keyword>HIV-1</keyword>
	<keyword>AIDS</keyword>
	<keyword>Human Immunodeficiency Virus</keyword>
	<keyword>HIV-1 Infection</keyword>
</DOC>